Genetic risk of immune response after blood transfusions in sickle cell disease
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study looks at whether certain genes make people with sickle cell disease more likely to develop an immune reaction to blood transfusions. It aims to help doctors predict transfusion risks and improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be older than 2 years and have sickle cell disease.
- You must have had at least 10 blood transfusions (or 20 units) in the past, or have had one or more antibody tests, or have a known genetic variant linked to transfusion reactions.
- You must not have impaired decision-making ability that prevents you from consenting (or having someone consent for you).
- You cannot have had an organ, bone marrow, or stem cell transplant.
- You must not be taking medications that suppress your immune system at the time of joining.
- If you can become pregnant, you must not be pregnant at the time of enrollment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects blood samples to learn more about sickle cell-related genetics and biology. You might benefit indirectly by helping researchers understand the condition, even though this is laboratory research rather than a medication trial.
This study collects blood and urine samples from adults to help researchers understand diseases affecting blood vessels. Your donation helps scientists develop better treatments.
This study tests a way to do a bone marrow (stem cell) transplant from an HLA-matched sibling in children with sickle cell disease, aiming to lower the risk of serious side effects. You may be considered if you have certain past sickle complications and your body can safely handle the transplant plan.
This study tests whether giving regular blood transfusions during early pregnancy can help prevent complications for women with sickle cell disease. If you are between 6 and 20 weeks pregnant, you may join to see if this treatment improves outcomes.
This study looks at how patients with sickle cell disease who had a stem cell transplant from a sibling are doing now, compared to patients who didn't have a transplant. It focuses on health status and quality of life over the long term.
This early-phase study tests whether a “half-matched” donor bone marrow transplant, with special medicines to calm the immune system before transplant, can improve outcomes for people with sickle cell disease. It may help high-risk patients who have frequent complications and don’t have a fully matched donor.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.